CLDF Title
Home | Contact Us | Bookmark
MASH HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
Embassy of Education
Webcasts Abstract Library LiverQ Academy National Conference Regional Conferences
 
Back  
 
Reuters Health Information (2005-02-03): Type 1 interferon augments murine response to DNA-based anti-HCV vaccine

Science

Type 1 interferon augments murine response to DNA-based anti-HCV vaccine

Last Updated: 2005-02-03 16:49:41 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Mice treated with type 1 interferon have enhanced responses to DNA vaccination against hepatitis C virus core protein, according to a report in the February issue of the Journal of Medical Virology.

At Brown Medical School in Providence, Rhode Island, Dr. Stephan Gehring and colleagues treated mice with two types of recombinant type 1 interferon proteins: hybrid interferon alpha A/D (also referred to as universal type 1 interferon), and human pegylated interferon alpha-2a. In addition, the researchers tested the effect of administration of a plasmid expressing murine interferon-alpha.

According to the article, analysis of conventional cytotoxic T lymphocyte assays and an in vivo tumor challenge model showed that low doses of hybrid interferon alpha A/D and pegylated interferon "augmented three to fourfold the cellular immune response to DNA-based vaccination."

"Importantly," the investigators add, "augmentation occurred within a narrow concentration range." Whereas low doses of both of these types of interferon induced strong augmentation of vaccination, increasing the doses resulted in significantly decreased augmentation.

Administration of the plasmid expressing murine interferon-alpha "strongly suppressed the specific cytotoxic T lymphocyte activity" of the vaccine, the researchers report.

These findings, they conclude, "demonstrate that the immunomodulatory properties of interferon-alpha can be exploited to augment DNA based immunization, but it is important to consider the effects of dose on both cellular and humoral immune response for optimal augmentation."

J Med Virol 2005;75:249-257

 
 
 
 

Subscribe

Be the first to know about our latest upcoming programs and events!

CLDF

Follow us

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2025 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.